Large scale registry shows atrial fibrillation management is suboptimal and unequal around the world
29 August 2012 | By Boehringer Ingelheim
New one-year follow-up results from the global RE-LY AF registry...
List view / Grid view
News
Renishaw announces Raman seminars at the STFC, Rutherford Appleton Laboratory
28 August 2012 | By Renishaw
Following the success of the Inside Raman seminar last year...
Lundbeck receives approval from Health Canada for Treanda®
28 August 2012 | By H. Lundbeck A/S
Lundbeck announced that Health Canada has approved Treanda® following the success of the brand in both Europe and the US...
Changes to the Roche Corporate Executive Committee
28 August 2012 | By Roche
Daniel O’Day appointed new Head of Roche Pharma– Roland Diggelmann will assume the position Head of Roche Diagnostics...
Novartis drug Jakavi® first medication to receive European Commission approval to treat patients with myelofibrosis
28 August 2012 | By Novartis
Novartis received approval today from the European Commission for Jakavi®...
Pascal Soriot appointed Chief Executive Officer of AstraZeneca
AstraZeneca today announced that Pascal Soriot has been appointed as the company’s Chief Executive Officer. Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012.
European Commission approves ZINFORO™ (ceftaroline fosamil) for adult patients with serious skin infections or community acquired pneumonia
28 August 2012 | By AstraZeneca
European Commission approves ZINFORO™...
Abbott announces CE Mark for highly sensitive testosterone test to measure the hormone at low levels
Abbott announced today CE Marking (Conformité Européenne) for a testosterone assay with improved sensitivity and clinical utility. With a simple blood test, the ARCHITECT 2nd Generation Testosterone Assay can accurately measure the wide range of testosterone levels seen in a number of different patient populations and clinical settings.
U.S. FDA approves Gilead’s Stribild™
27 August 2012 | By Gilead Sciences
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved StribildTM...
Clinical experience with Pradaxa® crosses one million patient-years of treatment
27 August 2012 | By Boehringer Ingelheim
40,000 people estimated to be saved from a stroke related to non-valvular atrial fibrillation...
Key results from new tiotropium studies in COPD and asthma to be presented at ERS 2012
27 August 2012 | By Boehringer Ingelheim
New data to be presented at the Annual Congress of the ERS 2012...
New data from Phase III EMILIA study showed Roche’s trastuzumab emtansine (T-DM1) significantly improved survival of people with HER2-positive metastatic breast cancer
27 August 2012 | By Roche
Pivotal study met co-primary efficacy endpoint of overall survival...
Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure
26 August 2012 | By Eli Lilly and Company
Study did not meet primary objective of demonstrating prasugrel superiority over clopidogrel in this patient population...
Merck provides update on cardiovascular development program
26 August 2012 | By Merck
Merck provided an update on the development programs for vorapaxar, extended release niacin/laropirprant and anacetrapib...
New Novartis Phase II data show LCZ696 may provide clinical benefits in patients with a difficult-to-treat form of heart failure
26 August 2012 | By Novartis
Novartis announced results from the Phase II PARAMOUNT study...
